Questions about MS? Call us on 0808 800 8000
Generic research

MIS416

MIS416 is a therapy currently in phase 2 trials for secondary progressive MS. It is being developed by Innate Immunotherapeutics.

In July 2017 researchers reported that MIS416 didn't show any benefits for people with secondary progressive MS. The company has announced that they will fully analyse the data before considering the next steps for the drug.

Current phase of trial:
Phase 2

Find out more about MIS416

How does MIS416 work?

MIS416 contains two molecules that alter the behaviour of certain immune cells, which may prevent the damage seen in MS. Research suggests that by targeting specific immune cells, MIS416 can reduce inflammation in the central nervous system (CNS).

How is MIS416 taken?

It's taken as an infusion once a week.

Latest MIS416 research

Phase 2 Clinical Trial

In July 2017 researchers reported that MIS416 didn't show any benefits for people with secondary progressive MS. The company has announced that they will fully analyse the data before considering the next steps for the drug.

This phase 2 study tested if weekly treatments of MIS416 could slow progression compared with placebo. Progression was measured by the Expanded Disability Status Scale (EDSS), and the trial involved 90 people with secondary progressive MS.

Earlier research

Phase 1/2 Clinical Trial

This phase 1/2 clinical trial was designed to determine the correct dose for further trials and assess the safety of MIS416 treatment. It involved 34 participants with progressive MS and the results were published in 2012.

The study determined that MIS416 was well tolerated at 500µg/week and the majority of adverse events were mild or moderate, including acute flu-like symptoms.

What are the side effects?

Generally, MIS416 was well tolerated with the most common side effects being fever, headache, fatigue and muscle weakness.

How does MIS416 compare with other therapies?

There are currently no treatments available for people with secondary progressive MS.

When is MIS416 likely to be available?

In July 2017 researchers reported that MIS416 didn't show any benefits for people with secondary progressive MS. The company has announced that they will fully analyse the data before considering the next steps for the drug.

Urgent appeal: Help us be there for everyone with MS

Urgent appeal: Help us be there for everyone with MS

£
Donate now
Donation type